Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry.
Methods for the determination of celecoxib in human plasma and rat microdialysis samples using liquid chromatography tandem mass spectrometry are described. Celecoxib and an internal standard were extracted from plasma by solid-phase extraction with C18 cartridges. Thereafter compounds were separated on a short narrow bore RP C18 column (30 x 2 mm). Microdialysis samples did not require extraction and were injected directly using a narrow bore RP C18 column (70 x 2 mm). The detection was by a PE Sciex API 3000 mass spectrometer equipped with a turbo ion spray interface. The compounds were detected in the negative ion mode using the mass transitions m/z 380-->316 and m/z 366-->302 for celecoxib and internal standard, respectively. The assay was validated for human plasma over a concentration range of 0.25-250 ng/ml using 0.2 ml of sample. The assay for microdialysis samples (50 microl) was validated over a concentration range of 0.5-20 ng/ml. The method was utilised to determine pharmacokinetics of celecoxib in human plasma and in rat spinal cord perfusate.
Bräutigam
L
L
Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt am Main, Germany.
Vetter
G
G
Tegeder
I
I
Heinkele
G
G
Geisslinger
G
G
D000818:Animals; D000068579:Celecoxib; D002853:Chromatography, Liquid / Q000379:methods*; D016861:Cyclooxygenase Inhibitors / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D017551:Microdialysis; D011720:Pyrazoles; D051381:Rats; D012015:Reference Standards; D015203:Reproducibility of Results; D013449:Sulfonamides / Q000097:blood* / Q000493:pharmacokinetics
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib